Close Menu

NEW YORK (GenomeWeb) – Elucigene Diagnostics, a maker of PCR-based molecular tests, is branching further into the reproductive health and in vitro fertilization markets with assays for recurrent pregnancy loss and Y-chromosome microdeletions that can cause male infertility.

The majority of the firm's tests use capillary electrophoresis instruments from Thermo Fisher's Applied Biosystems, Chris Jones, Elucigene's sales and marketing manager, told GenomeWeb in an interview this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.